Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI (HISTO-RAD)
Primary Purpose
Prostate Cancer Recurrent
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Histoscanning™ and multiparametric MRI
Sponsored by
About this trial
This is an interventional diagnostic trial for Prostate Cancer Recurrent
Eligibility Criteria
Inclusion Criteria:
- Patients with biochemical recurrence (Phoenix criteria: PSA nadir + 2 ng/ml) after radiation therapy for prostate cancer addressed for prostate biopsy OR Patients referred to our institution for biopsy-proven local recurrence after radiation therapy for prostate cancer but needing a re-assessment with biopsy (insufficient number of biopsy and/or imprecise location of positive biopsy and/or questionable diagnostic of recurrence)
- IRB-approved informed consent signed
Exclusion Criteria:
- Contraindication to MRI
- Contraindication to endorectal examination
- Contraindication to prostate biopsy
- History of allergy to gadolinium chelates
Sites / Locations
- Prof O. ROUVIERE
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Single arm
Arm Description
Single arm
Outcomes
Primary Outcome Measures
Evaluation of Histoscanning™ after radiation therapy in comparison to random and targeted biopsy.
Histoscanning and biopsy findings will be compared on a sextant by sextant basis. A mixed effects logistic regression model (with fixed and random effects) will be used to model the sensitivity and specificity of Histoscanning to correctly identify the presence or absence of cancer into prostate sextants.
Secondary Outcome Measures
Evaluation of multiparametric MRI after radiation therapy in comparison to random and targeted biopsy.
MRI and biopsy findings will be compared on a sextant by sextant basis. A mixed effects logistic regression model (with fixed and random effects) will be used to model the sensitivity and specificity of MRI to correctly identify the presence or absence of cancer into prostate sextants.
Full Information
NCT ID
NCT01857037
First Posted
March 28, 2012
Last Updated
February 26, 2015
Sponsor
Hospices Civils de Lyon
1. Study Identification
Unique Protocol Identification Number
NCT01857037
Brief Title
Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI
Acronym
HISTO-RAD
Official Title
Detection and Localization of Prostate Cancer Local Recurrences After Radiation Therapy Using Histoscanning™ and Multiparametric MRI
Study Type
Interventional
2. Study Status
Record Verification Date
April 2011
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Inclusion criteria:
Patients with biochemical recurrence (Phoenix criteria: PSA nadir + 2 ng/ml) after radiation therapy for prostate cancer addressed for prostate biopsy OR
Patients referred to our institution for biopsy-proven local recurrence after radiation therapy for prostate cancer but needing a re-assessment with biopsy (insufficient number of biopsy and/or imprecise location of positive biopsy and/or questionable diagnostic of recurrence)
Study Design:
Included patients will undergo an endorectal US examination with a Histoscanning™ acquisition and a multiparametric (T2-weighted, diffusion-weighted and dynamic contrast-enhanced) MRI.
Two independent operators will separately define suspicious focal lesion on Histoscanning™ images and on MR images.
Random biopsies (at least 2 cores) will be performed in sextants negative at Histoscanning™ and at MRI ; In sextants positive at Histoscanning™ and/or at MRI, targeted biopsies will be performed in the suspicious part of the sextant (at least two cores per suspicious lesion).
Histoscanning™ and MRI results will be compared to biopsy results.
A total of 30 patients will be included
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer Recurrent
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Single arm
Arm Type
Other
Arm Description
Single arm
Intervention Type
Other
Intervention Name(s)
Histoscanning™ and multiparametric MRI
Intervention Description
Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
Primary Outcome Measure Information:
Title
Evaluation of Histoscanning™ after radiation therapy in comparison to random and targeted biopsy.
Description
Histoscanning and biopsy findings will be compared on a sextant by sextant basis. A mixed effects logistic regression model (with fixed and random effects) will be used to model the sensitivity and specificity of Histoscanning to correctly identify the presence or absence of cancer into prostate sextants.
Time Frame
1 day
Secondary Outcome Measure Information:
Title
Evaluation of multiparametric MRI after radiation therapy in comparison to random and targeted biopsy.
Description
MRI and biopsy findings will be compared on a sextant by sextant basis. A mixed effects logistic regression model (with fixed and random effects) will be used to model the sensitivity and specificity of MRI to correctly identify the presence or absence of cancer into prostate sextants.
Time Frame
1 day
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with biochemical recurrence (Phoenix criteria: PSA nadir + 2 ng/ml) after radiation therapy for prostate cancer addressed for prostate biopsy OR Patients referred to our institution for biopsy-proven local recurrence after radiation therapy for prostate cancer but needing a re-assessment with biopsy (insufficient number of biopsy and/or imprecise location of positive biopsy and/or questionable diagnostic of recurrence)
IRB-approved informed consent signed
Exclusion Criteria:
Contraindication to MRI
Contraindication to endorectal examination
Contraindication to prostate biopsy
History of allergy to gadolinium chelates
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olivier Rouvière, Pr
Organizational Affiliation
Hospices Civiles de Lyon
Official's Role
Principal Investigator
Facility Information:
Facility Name
Prof O. ROUVIERE
City
Lyon
State/Province
Rhône
ZIP/Postal Code
69437
Country
France
12. IPD Sharing Statement
Learn more about this trial
Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI
We'll reach out to this number within 24 hrs